181871-73-8

Basic information

• Product Name: 4-METHOXY-2-NITRO-BENZOIC ACID METHYL ESTER
• Synonyms: 4-METHOXY-2-NITRO-BENZOIC ACID METHYL ESTER;METHYL 4-METHOXY-2-NITROBENZOATE;Benzoic acid, 4-Methoxy-2-nitro-, Methyl ester
• CAS NO: 181871-73-8
• Molecular Formula: C9H9NO5
• Molecular Weight: 211.17
• Product Categories: blocks;Carboxes
• Mol File: 181871-73-8.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 336 °C at 760 mmHg
• Flash Point: 158.5 °C
• Appearance: /
• Density: 1.294 g/cm³
• Vapor Pressure: 0.000116mmHg at 25°C
• Refractive Index: 1.54
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: 4-METHOXY-2-NITRO-BENZOIC ACID METHYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: 4-METHOXY-2-NITRO-BENZOIC ACID METHYL ESTER(181871-73-8)
• EPA Substance Registry System: 4-METHOXY-2-NITRO-BENZOIC ACID METHYL ESTER(181871-73-8)

Safety Data

• Hazard Codes: Xi
• Hazardous Substances Data: 181871-73-8(Hazardous Substances Data)

Usage

General Description

4-Methoxy-2-nitro-benzoic acid methyl ester is a chemical compound with the molecular formula C9H9NO5. It is a methyl ester derivative of 4-methoxy-2-nitrobenzoic acid, and it is used in various chemical and pharmaceutical applications. 4-METHOXY-2-NITRO-BENZOIC ACID METHYL ESTER is a yellow solid with a molecular weight of 211.17 g/mol. It is soluble in organic solvents such as methanol, ethanol, and acetone, and it is used as a building block in the synthesis of various pharmaceutical compounds. It is important to handle this compound with caution as it may be harmful if ingested or inhaled and may cause skin and eye irritation.

InChI:InChI=1/C9H9NO5/c1-14-6-3-4-7(9(11)15-2)8(5-6)10(12)13/h3-5H,1-2H3

Upstream product

• 33844-21-2 2-nitro-4-methoxybenzoic acid 
• 74-88-4 methyl iodide 
• 67-56-1 methanol 
• 158580-57-5 methyl 4-bromo-2-nitrobenzoate 

Downstream Products

• 1221497-10-4 2-amino-4-methoxybenzhydrazide 

Relevant articles and documents

Development of Potent Inhibitors of Fatty Acid Amide Hydrolase Useful for the Treatment of Neuropathic Pain

The unique role of fatty acid amide hydrolase (FAAH) in terminating endocannabinoid (EC) signaling supports its relevance as a therapeutic target. Inhibition of EC metabolizing enzymes elicits indirect agonism of cannabinoid receptors (CBRs) and therapeutic efficacy devoid of psychotropic effects. Based on our previous ligands, and aiming at the discovery of new selective FAAH inhibitors, we developed a series of 12 new compounds characterized by functionalized tricyclic scaffolds. All the developed compounds display negligible activity on monoacylglycerol lipase (MAGL) and CBRs. The most potent FAAH inhibitors of the newly developed series, 6-oxo-5,6-dihydro-4H-benzo[f]pyrrolo[1,2-a][1,4]diazepin-9-yl-6-phenylhexylcarbamate (5 h) and 4-oxo-5,6-dihydro-4H-benzo[f]pyrrolo[1,2-a][1,4]diazepin-9-yl-(6-phenylhexyl)carbamate (5 i) (nanomolar FAAH inhibitors, the latter of which also shows micromolar affinity at the CB1R), were selected for further studies. Results of cell-based studies on a neuroblastoma cell line (IMR32) demonstrated 5 h, 5 i, and our reference compound 3 ([3-(3-carbamoylpyrrol-1-yl)phenyl] N-(5-phenylpentyl)carbamate) to lack any cytotoxic effect, while all three showed the ability to decrease oxidative stress by reducing the expression of the redox-sensitive transcription factor NF-κB. Encouraged by these data, these compounds were studied in vivo and were dosed orally in a mouse model of neuropathic pain. At 10 mg kg?1 all the compounds were able to relieve the hypersensitivity induced by oxaliplatin.

QUINOXALINE COMPOUNDS AND USE THEREOF

The present invention is related to quinoxaline compounds of Formula (I) in particular for the treatment of autoimmune disorders and/or inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, bacterial or viral infections, kidney diseases, platelet aggregation, cancer, transplantation, graft rejection or lung injuries.